San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...

From weight loss percentages to steps and sleep, discover which health numbers actually matter. And why more isn't ...

Pfizer revised its revenue expectations for 2025 and detailed its outlook for 2026. Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in ...

Fintel reports that on December 9, 2025, BERENBERG upgraded their outlook for Novo Nordisk A (OTCPK:NONOF) from Hold to Buy. Analyst Price Forecast Suggests 54.52% Downside As of December 6, 2025, the ...

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Upstart biotech company Viking Therapeutics (NASDAQ: VKTX) is a potential takeover candidate in 2026. That's not a reason to ...

USA News Group News Commentary - Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant that eliminates the need for insulin or ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...